Wild type p53 reactivation: From lab bench to clinic

FEBS Letters

Volumn 588, Issue 16, 2014, Pages 2628-2638

  Selivanova, Galina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Mdm2; MdmX; p53; ROS; Small molecule

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; CX 5461; LEPTOMYCIN B; MI 888; MUTANT PROTEIN; NUTLIN; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; RG 7112; RG 7388; RITA; RO 5963; ROSCOVITINE; SCH 529074; SERDEMETAN; SJ 172550; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL FATE; DNA REPAIR; DRUG SCREENING; ENZYME INHIBITION; GENE ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; MDM2; MDMX; P53; ROS; SMALL MOLECULE;

ANIMALS; HUMANS; LABORATORIES; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; SMALL MOLECULE LIBRARIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905105361     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.03.049     Document Type: Review

References (152)

1. C.P. Martins, L. Brown-Swigart, and G.I. Evan Modeling the therapeutic efficacy of p53 restoration in tumors Cell 127 2006 1323 1334
2. A. Ventura, D.G. Kirsch, M.E. McLaughlin, D.A. Tuveson, J. Grimm, L. Lintault, J. Newman, E.E. Reczek, R. Weissleder, and T. Jacks Restoration of p53 function leads to tumour regression in vivo Nature 445 2007 661 665
3. W. Xue, L. Zender, C. Miething, R.A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, and S.W. Lowe Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature 445 2007 656 660
4. M.A. Christophorou, D. Martin-Zanca, L. Soucek, E.R. Lawlor, L. Brown-Swigart, E.W. Verschuren, and G.I. Evan Temporal dissection of p53 function in vitro and in vivo Nat. Genet. 37 2005 718 726
5. K.H. Vousden, and C. Prives Blinded by the light: the growing complexity of p53 Cell 137 2009 413 431
6. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
7. T. Sjoblom, S. Jones, L.D. Wood, D.W. Parsons, J. Lin, T.D. Barber, D. Mandelker, R.J. Leary, J. Ptak, N. Silliman, S. Szabo, P. Buckhaults, C. Farrell, P. Meeh, S.D. Markowitz, J. Willis, D. Dawson, J.K. Willson, A.F. Gazdar, J. Hartigan, L. Wu, C. Liu, G. Parmigiani, B.H. Park, K.E. Bachman, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, and V.E. Velculescu The consensus coding sequences of human breast and colorectal cancers Science (New York, NY) 314 2006 268 274
8. M.S. Lawrence, P. Stojanov, P. Polak, G.V. Kryukov, K. Cibulskis, A. Sivachenko, S.L. Carter, C. Stewart, C.H. Mermel, S.A. Roberts, A. Kiezun, P.S. Hammerman, A. McKenna, Y. Drier, L. Zou, A.H. Ramos, T.J. Pugh, N. Stransky, E. Helman, J. Kim, C. Sougnez, L. Ambrogio, E. Nickerson, E. Shefler, M.L. Cortes, D. Auclair, G. Saksena, D. Voet, M. Noble, D. DiCara, P. Lin, L. Lichtenstein, D.I. Heiman, T. Fennell, M. Imielinski, B. Hernandez, E. Hodis, S. Baca, A.M. Dulak, J. Lohr, D.A. Landau, C.J. Wu, J. Melendez-Zajgla, A. Hidalgo-Miranda, A. Koren, S.A. McCarroll, J. Mora, R.S. Lee, B. Crompton, R. Onofrio, M. Parkin, W. Winckler, K. Ardlie, S.B. Gabriel, C.W. Roberts, J.A. Biegel, K. Stegmaier, A.J. Bass, L.A. Garraway, M. Meyerson, T.R. Golub, D.A. Gordenin, S. Sunyaev, E.S. Lander, and G. Getz Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 499 2013 214 218
9. V.J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K.G. Wiman, and G. Selivanova Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound Nat. Med. 8 2002 282 288
10. G. Selivanova, and K.G. Wiman Reactivation of mutant p53: molecular mechanisms and therapeutic potential Oncogene 26 2007 2243 2254
11. S.N. Jones, A.E. Roe, L.A. Donehower, and A. Bradley Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 Nature 378 1995 206 208
12. R. Montes de Oca Luna, D.S. Wagner, and G. Lozano Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 Nature 378 1995 203 206
13. J. Parant, A. Chavez-Reyes, N.A. Little, W. Yan, V. Reinke, A.G. Jochemsen, and G. Lozano Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 Nat. Genet. 29 2001 92 95
14. Q. Li, and G. Lozano Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy Clin. Cancer Res. 19 2013 34 41
15. J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
16. M.A. Lohrum, D.B. Woods, R.L. Ludwig, E. Balint, and K.H. Vousden C-terminal ubiquitination of p53 contributes to nuclear export Mol. Cell. Biol. 21 2001 8521 8532
17. M.H. Kubbutat, S.N. Jones, and K.H. Vousden Regulation of p53 stability by Mdm2 Nature 387 1997 299 303
18. Y. Haupt, R. Maya, A. Kazaz, and M. Oren Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299
19. Y. Ofir-Rosenfeld, K. Boggs, D. Michael, M.B. Kastan, and M. Oren Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26 Mol. Cell 32 2008 180 189
20. R. Stad, N.A. Little, D.P. Xirodimas, R. Frenk, A.J. van der Eb, D.P. Lane, M.K. Saville, and A.G. Jochemsen Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms EMBO Rep. 2 2001 1029 1034
21. M. Wade, Y.C. Li, and G.M. Wahl MDM2, MDMX and p53 in oncogenesis and cancer therapy Nat. Rev. Cancer 13 2013 83 96
22. K. Onel, and C. Cordon-Cardo MDM2 and prognosis Mol. Cancer Res. 2 2004 1 8
23. J.C. Marine MDM2 and MDMX in cancer and development Curr. Top. Dev. Biol. 94 2011 45 75
24. G.L. Bond, W. Hu, E.E. Bond, H. Robins, S.G. Lutzker, N.C. Arva, J. Bargonetti, F. Bartel, H. Taubert, P. Wuerl, K. Onel, L. Yip, S.J. Hwang, L.C. Strong, G. Lozano, and A.J. Levine A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 2004 591 602
25. V. Grinkevich, A. Warnecke, and G. Selivanova P53-Reactivating Molecules as Research Tools and Anticancer Drugs 2013 Springer New York
26. L.T. Vassilev MDM2 inhibitors for cancer therapy Trends Mol. Med. 13 2007 23 31
27. S. Nag, X. Zhang, K.S. Srivenugopal, M.H. Wang, W. Wang, and R. Zhang Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr. Med. Chem. 21 2014 553 574
28. K.K. Hoe, C.S. Verma, and D.P. Lane Drugging the p53 pathway: understanding the route to clinical efficacy Nat. Rev. Drug Discovery 13 2014 217 236
29. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E.A. Liu In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
30. K. Ding, Y. Lu, Z. Nikolovska-Coleska, G. Wang, S. Qiu, S. Shangary, W. Gao, D. Qin, J. Stuckey, K. Krajewski, P.P. Roller, and S. Wang Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 49 2006 3432 3435
31. B.L. Grasberger, T. Lu, C. Schubert, D.J. Parks, T.E. Carver, H.K. Koblish, M.D. Cummings, L.V. LaFrance, K.L. Milkiewicz, R.R. Calvo, D. Maguire, J. Lattanze, C.F. Franks, S. Zhao, K. Ramachandren, G.R. Bylebyl, M. Zhang, C.L. Manthey, E.C. Petrella, M.W. Pantoliano, I.C. Deckman, J.C. Spurlino, A.C. Maroney, B.E. Tomczuk, C.J. Molloy, and R.F. Bone Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells J. Med. Chem. 48 2005 909 912
32. A. Mullard Protein-protein interaction inhibitors get into the groove Nat. Rev. Drug Discovery 11 2012 173 175
33. Y. Zhao, S. Yu, W. Sun, L. Liu, J. Lu, D. McEachern, S. Shargary, D. Bernard, X. Li, T. Zhao, P. Zou, D. Sun, and S. Wang A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice J. Med. Chem. 56 2013 5553 5561
34. I. Ray-Coquard, J.Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, F. Heil, R. Rueger, B. Graves, M. Ding, D. Geho, S.A. Middleton, L.T. Vassilev, G.L. Nichols, and B.N. Bui Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study Lancet Oncol. 13 2012 1133 1140
35. Q. Ding, Z. Zhang, J.J. Liu, N. Jiang, J. Zhang, T.M. Ross, X.J. Chu, D. Bartkovitz, F. Podlaski, C. Janson, C. Tovar, Z.M. Filipovic, B. Higgins, K. Glenn, K. Packman, L.T. Vassilev, and B. Graves Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 56 2013 5979 5983
36. C. Tovar, J. Rosinski, Z. Filipovic, B. Higgins, K. Kolinsky, H. Hilton, X. Zhao, B.T. Vu, W. Qing, K. Packman, O. Myklebost, D.C. Heimbrook, and L.T. Vassilev Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proc. Natl. Acad. Sci. USA 103 2006 1888 1893
37. M. Xia, D. Knezevic, C. Tovar, B. Huang, D.C. Heimbrook, and L.T. Vassilev Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation Cell Cycle 7 2008 1604 1612
38. M. Wade, E.T. Wong, M. Tang, J.M. Stommel, and G.M. Wahl Hdmx modulates the outcome of p53 activation in human tumor cells J. Biol. Chem. 281 2006 33036 33044
39. B. Hu, D.M. Gilkes, B. Farooqi, S.M. Sebti, and J. Chen MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin J. Biol. Chem. 281 2006 33030 33035
40. N.A. Laurie, S.L. Donovan, C.S. Shih, J. Zhang, N. Mills, C. Fuller, A. Teunisse, S. Lam, Y. Ramos, A. Mohan, D. Johnson, M. Wilson, C. Rodriguez-Galindo, M. Quarto, S. Francoz, S.M. Mendrysa, R.K. Guy, J.C. Marine, A.G. Jochemsen, and M.A. Dyer Inactivation of the p53 pathway in retinoblastoma Nature 444 2006 61 66
41. D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P.G. Pelicci, A.G. Jochemsen, and J.C. Marine Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity Mol. Cell. Biol. 24 2004 5835 5843
42. A. Gembarska, F. Luciani, C. Fedele, E.A. Russell, M. Dewaele, S. Villar, A. Zwolinska, S. Haupt, J. de Lange, D. Yip, J. Goydos, J.J. Haigh, Y. Haupt, L. Larue, A. Jochemsen, H. Shi, G. Moriceau, R.S. Lo, G. Ghanem, M. Shackleton, F. Bernal, and J.C. Marine MDM4 is a key therapeutic target in cutaneous melanoma Nat. Med. 18 2012 1239 1247
43. D. Reed, Y. Shen, A.A. Shelat, L.A. Arnold, A.M. Ferreira, F. Zhu, N. Mills, D.C. Smithson, C.A. Regni, D. Bashford, S.A. Cicero, B.A. Schulman, A.G. Jochemsen, R.K. Guy, and M.A. Dyer Identification and characterization of the first small molecule inhibitor of MDMX J. Biol. Chem. 285 2010 10786 10796
44. H. Wang, X. Ma, S. Ren, J.K. Buolamwini, and C. Yan A small-molecule inhibitor of MDMX activates p53 and induces apoptosis Mol. Cancer Ther. 10 2011 69 79
45. B. Graves, T. Thompson, M. Xia, C. Janson, C. Lukacs, D. Deo, P. Di Lello, D. Fry, C. Garvie, K.S. Huang, L. Gao, C. Tovar, A. Lovey, J. Wanner, and L.T. Vassilev Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization Proc. Natl. Acad. Sci. USA 109 2012 11788 11793
46. J.H. Lee, Q. Zhang, S. Jo, S.C. Chai, M. Oh, W. Im, H. Lu, and H.S. Lim Novel pyrrolopyrimidine-based alpha-helix mimetics: cell-permeable inhibitors of protein-protein interactions J. Am. Chem. Soc. 133 2011 676 679
47. S.M. Vogel, M.R. Bauer, A.C. Joerger, R. Wilcken, T. Brandt, D.B. Veprintsev, T.J. Rutherford, A.R. Fersht, and F.M. Boeckler Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2 Proc. Natl. Acad. Sci. USA 109 2012 16906 16910
48. N. Issaeva, P. Bozko, M. Enge, M. Protopopova, L.G. Verhoef, M. Masucci, A. Pramanik, and G. Selivanova Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors Nat. Med. 10 2004 1321 1328
49. M. Enge, W. Bao, E. Hedstrom, S.P. Jackson, A. Moumen, and G. Selivanova MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53 Cancer Cell 15 2009 171 183
50. C. Spinnler, E. Hedstrom, H. Li, J. de Lange, F. Nikulenkov, A.F. Teunisse, M. Verlaan-de Vries, V. Grinkevich, A.G. Jochemsen, and G. Selivanova Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX Cell Death Differ. 18 2011 1736 1745
51. I.V. Davydov, D. Woods, Y.J. Safiran, P. Oberoi, H.O. Fearnhead, S. Fang, J.P. Jensen, A.M. Weissman, J.H. Kenten, and K.H. Vousden Assay for ubiquitin ligase activity: high-throughput screen for inhibitors of HDM2 J. Biomol. Screen. 9 2004 695 703
52. J. Kitagaki, K.K. Agama, Y. Pommier, Y. Yang, and A.M. Weissman Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2 Mol. Cancer Ther. 7 2008 2445 2454
53. C.A. Sasiela, D.H. Stewart, J. Kitagaki, Y.J. Safiran, Y. Yang, A.M. Weissman, P. Oberoi, I.V. Davydov, E. Goncharova, J.A. Beutler, J.B. McMahon, and B.R. O'Keefe Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen J. Biomol. Screen. 13 2008 229 237
54. A.G. Herman, M. Hayano, M.V. Poyurovsky, K. Shimada, R. Skouta, C. Prives, and B.R. Stockwell Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay Cancer Discovery 1 2011 312 325
55. K. Kojima, J.K. Burks, J. Arts, and M. Andreeff The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias Mol. Cancer Ther. 9 2010 2545 2557
56. J. Tabernero, L. Dirix, P. Schoffski, A. Cervantes, J.A. Lopez-Martin, J. Capdevila, L. van Beijsterveldt, S. Platero, B. Hall, Z. Yuan, R. Knoblauch, and S.H. Zhuang A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors Clin. Cancer Res. 17 2011 6313 6321
57. A. Bottger, V. Bottger, A. Sparks, W.L. Liu, S.F. Howard, and D.P. Lane Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo Curr. Biol. 7 1997 860 869
58. P. Chene, J. Fuchs, J. Bohn, C. Garcia-Echeverria, P. Furet, and D. Fabbro A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines J. Mol. Biol. 299 2000 245 253
59. F. Bernal, A.F. Tyler, S.J. Korsmeyer, L.D. Walensky, and G.L. Verdine Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide J. Am. Chem. Soc. 129 2007 2456 2457
60. Y.S. Chang, B. Graves, V. Guerlavais, C. Tovar, K. Packman, K.H. To, K.A. Olson, K. Kesavan, P. Gangurde, A. Mukherjee, T. Baker, K. Darlak, C. Elkin, Z. Filipovic, F.Z. Qureshi, H. Cai, P. Berry, E. Feyfant, X.E. Shi, J. Horstick, D.A. Annis, A.M. Manning, N. Fotouhi, H. Nash, L.T. Vassilev, and T.K. Sawyer Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy Proc. Natl. Acad. Sci. USA 110 2013 E3445 E3454
61. M.A. Lohrum, R.L. Ludwig, M.H. Kubbutat, M. Hanlon, and K.H. Vousden Regulation of HDM2 activity by the ribosomal protein L11 Cancer Cell 3 2003 577 587
62. C.P. Rubbi, and J. Milner Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses EMBO J. 22 2003 6068 6077
63. I.H. Goldberg The interaction of actinomycin with DNA Antibiot. Chemother. 17 1971 67 86
64. M.L. Choong, H. Yang, M.A. Lee, and D.P. Lane Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy Cell Cycle 8 2009 2810 2818
65. K. Peltonen, L. Colis, H. Liu, S. Jaamaa, H.M. Moore, J. Enback, P. Laakkonen, A. Vaahtokari, R.J. Jones, T.M. af Hallstrom, and M. Laiho Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents PLoS One 5 2010 e12996
66. K. Peltonen, L. Colis, H. Liu, R. Trivedi, M.S. Moubarek, H.M. Moore, B. Bai, M.A. Rudek, C.J. Bieberich, and M. Laiho A targeting modality for destruction of RNA polymerase I that possesses anticancer activity Cancer Cell 25 2014 77 90
67. M.J. Bywater, G. Poortinga, E. Sanij, N. Hein, A. Peck, C. Cullinane, M. Wall, L. Cluse, D. Drygin, K. Anderes, N. Huser, C. Proffitt, J. Bliesath, M. Haddach, M.K. Schwaebe, D.M. Ryckman, W.G. Rice, C. Schmitt, S.W. Lowe, R.W. Johnstone, R.B. Pearson, G.A. McArthur, and R.D. Hannan Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53 Cancer Cell 22 2012 51 65
68. W. Lu, L. Chen, Y. Peng, and J. Chen Activation of p53 by roscovitine-mediated suppression of MDM2 expression Oncogene 20 2001 3206 3216
69. S.C. Mutka, W.Q. Yang, S.D. Dong, S.L. Ward, D.A. Craig, P.B. Timmermans, and S. Murli Identification of nuclear export inhibitors with potent anticancer activity in vivo Cancer Res. 69 2009 510 517
70. C. Dai, and W. Gu P53 post-translational modification: deregulated in tumorigenesis Trends Mol. Med. 16 2010 528 536
71. H. Vaziri, S.K. Dessain, E. Ng Eaton, S.I. Imai, R.A. Frye, T.K. Pandita, L. Guarente, and R.A. Weinberg HSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase Cell 107 2001 149 159
72. S. Lain, J.J. Hollick, J. Campbell, O.D. Staples, M. Higgins, M. Aoubala, A. McCarthy, V. Appleyard, K.E. Murray, L. Baker, A. Thompson, J. Mathers, S.J. Holland, M.J. Stark, G. Pass, J. Woods, D.P. Lane, and N.J. Westwood Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell 13 2008 454 463
73. Q. Zhang, S.X. Zeng, Y. Zhang, Y. Zhang, D. Ding, Q. Ye, S.O. Meroueh, and H. Lu A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53 EMBO Mol. Med. 4 2012 298 312
74. K.V. Gurova, J.E. Hill, C. Guo, A. Prokvolit, L.G. Burdelya, E. Samoylova, A.V. Khodyakova, R. Ganapathi, M. Ganapathi, N.D. Tararova, D. Bosykh, D. Lvovskiy, T.R. Webb, G.R. Stark, and A.V. Gudkov Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors Proc. Natl. Acad. Sci. USA 102 2005 17448 17453
75. A.V. Gasparian, C.A. Burkhart, A.A. Purmal, L. Brodsky, M. Pal, M. Saranadasa, D.A. Bosykh, M. Commane, O.A. Guryanova, S. Pal, A. Safina, S. Sviridov, I.E. Koman, J. Veith, A.A. Komar, A.V. Gudkov, and K.V. Gurova Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT Science Transl. Med. 3 2011 95ra74
76. H. Garcia, J.C. Miecznikowski, A. Safina, M. Commane, A. Ruusulehto, S. Kilpinen, R.W. Leach, K. Attwood, Y. Li, S. Degan, A.R. Omilian, O. Guryanova, O. Papantonopoulou, J. Wang, M. Buck, S. Liu, C. Morrison, and K.V. Gurova Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers Cell Rep. 4 2013 159 173
77. C.Y. Zhao, V.V. Grinkevich, F. Nikulenkov, W. Bao, and G. Selivanova Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA Cell Cycle 9 2010 1847 1855
78. C.Y. Zhao, L. Szekely, W. Bao, and G. Selivanova Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation Cancer Res. 70 2010 3372 3381
79. M. Burmakin, Y. Shi, E. Hedstrom, P. Kogner, and G. Selivanova Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro Clin. Cancer Res. 19 2013 5092 5103
80. M. Demma, E. Maxwell, R. Ramos, L. Liang, C. Li, D. Hesk, R. Rossman, A. Mallams, R. Doll, M. Liu, C. Seidel-Dugan, W.R. Bishop, and B. Dasmahapatra SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53 J. Biol. Chem. 285 2010 10198 10212
81. N. Issaeva, A. Friedler, P. Bozko, K.G. Wiman, A.R. Fersht, and G. Selivanova Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide Proc. Natl. Acad. Sci. USA 100 2003 13303 13307
82. M. Wallace, E. Worrall, S. Pettersson, T.R. Hupp, and K.L. Ball Dual-site regulation of MDM2 E3-ubiquitin ligase activity Mol. Cell 23 2006 251 263
83. L. Weinmann, J. Wischhusen, M.J. Demma, U. Naumann, P. Roth, B. Dasmahapatra, and M. Weller A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis Cell Death Differ. 15 2008 718 729
84. W. Bao, M. Chen, X. Zhao, R. Kumar, C. Spinnler, M. Thullberg, N. Issaeva, G. Selivanova, and S. Stromblad PRIMA-1 (Met)/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo Cell Cycle 10 2011 301 307
85. M.H. Aziz, H. Shen, and C.G. Maki Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 Oncogene 30 2011 4678 4686
86. M. Michaelis, F. Rothweiler, S. Barth, J. Cinatl, M. van Rikxoort, N. Loschmann, Y. Voges, R. Breitling, A. von Deimling, F. Rodel, K. Weber, B. Fehse, E. Mack, T. Stiewe, H.W. Doerr, D. Speidel, and J. Cinatl Jr. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells Cell Death Dis. 2 2011 e243
87. A.L. Okorokov, M.B. Sherman, C. Plisson, V. Grinkevich, K. Sigmundsson, G. Selivanova, J. Milner, and E.V. Orlova The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity EMBO J. 25 2006 5191 5200
88. H. Tidow, R. Melero, E. Mylonas, S.M. Freund, J.G. Grossmann, J.M. Carazo, D.I. Svergun, M. Valle, and A.R. Fersht Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex Proc. Natl. Acad. Sci. USA 104 2007 12324 12329
89. D. Jiang, C.A. Brady, T.M. Johnson, E.Y. Lee, E.J. Park, M.P. Scott, and L.D. Attardi Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages Proc. Natl. Acad. Sci. USA 108 2011 17123 17128
90. M.A. Christophorou, I. Ringshausen, A.J. Finch, L.B. Swigart, and G.I. Evan The pathological response to DNA damage does not contribute to p53-mediated tumour suppression Nature 443 2006 214 217
91. C.A. Brady, D. Jiang, S.S. Mello, T.M. Johnson, L.A. Jarvis, M.M. Kozak, D. Kenzelmann Broz, S. Basak, E.J. Park, M.E. McLaughlin, A.N. Karnezis, and L.D. Attardi Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression Cell 145 2011 571 583
92. O. Timofeev, K. Schlereth, M. Wanzel, A. Braun, B. Nieswandt, A. Pagenstecher, A. Rosenwald, H.P. Elsasser, and T. Stiewe P53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo Cell Rep. 3 2013 1512 1525
93. T. Li, N. Kon, L. Jiang, M. Tan, T. Ludwig, Y. Zhao, R. Baer, and W. Gu Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence Cell 149 2012 1269 1283
94. L.J. Valente, D.H. Gray, E.M. Michalak, J. Pinon-Hofbauer, A. Egle, C.L. Scott, A. Janic, and A. Strasser P53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa Cell Rep. 3 2013 1339 1345
95. A.A. Sablina, A.V. Budanov, G.V. Ilyinskaya, L.S. Agapova, J.E. Kravchenko, and P.M. Chumakov The antioxidant function of the p53 tumor suppressor Nat. Med. 11 2005 1306 1313
96. S.A. Gatz, and L. Wiesmuller P53 in recombination and repair Cell Death Differ. 13 2006 1003 1016
97. D. Kenzelmann Broz, S. Spano Mello, K.T. Bieging, D. Jiang, R.L. Dusek, C.A. Brady, A. Sidow, and L.D. Attardi Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses Genes Dev. 27 2013 1016 1031
98. D. Crighton, S. Wilkinson, J. O'Prey, N. Syed, P. Smith, P.R. Harrison, M. Gasco, O. Garrone, T. Crook, and K.M. Ryan DRAM, a p53-induced modulator of autophagy, is critical for apoptosis Cell 126 2006 121 134
99. Y. Huo, H. Cai, I. Teplova, C. Bowman-Colin, G. Chen, S. Price, N. Barnard, S. Ganesan, V. Karantza, E. White, and B. Xia Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer Cancer Discovery 3 2013 894 907
100. J.Y. Guo, G. Karsli-Uzunbas, R. Mathew, S.C. Aisner, J.J. Kamphorst, A.M. Strohecker, G. Chen, S. Price, W. Lu, X. Teng, E. Snyder, U. Santanam, R.S. Dipaola, T. Jacks, J.D. Rabinowitz, and E. White Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis Genes Dev. 27 2013 1447 1461
101. M.T. Rosenfeldt, J. O'Prey, J.P. Morton, C. Nixon, G. MacKay, A. Mrowinska, A. Au, T.S. Rai, L. Zheng, R. Ridgway, P.D. Adams, K.I. Anderson, E. Gottlieb, O.J. Sansom, and K.M. Ryan P53 status determines the role of autophagy in pancreatic tumour development Nature 504 2013 296 300
102. S. Schwitalla, P.K. Ziegler, D. Horst, V. Becker, I. Kerle, Y. Begus-Nahrmann, A. Lechel, K.L. Rudolph, R. Langer, J. Slotta-Huspenina, F.G. Bader, O. Prazeres da Costa, M.F. Neurath, A. Meining, T. Kirchner, and F.R. Greten Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors Cancer Cell 23 2013 93 106
103. A. Lujambio, L. Akkari, J. Simon, D. Grace, D.F. Tschaharganeh, J.E. Bolden, Z. Zhao, V. Thapar, J.A. Joyce, V. Krizhanovsky, and S.W. Lowe Non-cell-autonomous tumor suppression by p53 Cell 153 2013 449 460
104. S. Textor, N. Fiegler, A. Arnold, A. Porgador, T.G. Hofmann, and A. Cerwenka Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2 Cancer Res. 71 2011 5998 6009
105. H. Li, T. Lakshmikanth, C. Garofalo, M. Enge, C. Spinnler, A. Anichini, L. Szekely, K. Karre, E. Carbone, and G. Selivanova Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2 Cell Cycle 10 2011 3346 3358
106. M. Taura, A. Eguma, M.A. Suico, T. Shuto, T. Koga, K. Komatsu, T. Komune, T. Sato, H. Saya, J.D. Li, and H. Kai P53 regulates toll-like receptor 3 expression and function in human epithelial cell lines Mol. Cell. Biol. 28 2008 6557 6567
107. B. Wang, D. Niu, L. Lai, and E.C. Ren P53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1 Nat. Commun. 4 2013 2359
108. J.G. Jackson, V. Pant, Q. Li, L.L. Chang, A. Quintas-Cardama, D. Garza, O. Tavana, P. Yang, T. Manshouri, Y. Li, A.K. El-Naggar, and G. Lozano P53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer Cancer Cell 21 2012 793 806
109. J. Ablain, K. Rice, H. Soilihi, A. de Reynies, S. Minucci, and H. de The Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure Nat. Med. 20 2014 167 174
110. F. Nikulenkov, C. Spinnler, H. Li, C. Tonelli, Y. Shi, M. Turunen, T. Kivioja, I. Ignatiev, A. Kel, J. Taipale, and G. Selivanova Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis Cell Death Differ. 19 2012 1992 2002
111. J.P. Kruse, and W. Gu SnapShot: p53 posttranslational modifications Cell 133 930-30 2008 e1
112. J.P. Kruse, and W. Gu Modes of p53 regulation Cell 137 2009 609 622
113. G. D'Orazi, B. Cecchinelli, T. Bruno, I. Manni, Y. Higashimoto, S. Saito, M. Gostissa, S. Coen, A. Marchetti, G. Del Sal, G. Piaggio, M. Fanciulli, E. Appella, and S. Soddu Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis Nat. Cell Biol. 4 2002 11 19
114. X. Lu P53: a heavily dictated dictator of life and death Curr. Opin. Genet. Dev. 15 2005 27 33
115. A. Moumen, P. Masterson, M.J. O'Connor, and S.P. Jackson HnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage Cell 123 2005 1065 1078
116. T.K. MacLachlan, R. Takimoto, and W.S. El-Deiry BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets Mol. Cell. Biol. 22 2002 4280 4292
117. Y.R. Seo, M.R. Kelley, and M.L. Smith Selenomethionine regulation of p53 by a ref1-dependent redox mechanism Proc. Natl. Acad. Sci. USA 99 2002 14548 14553
118. Y. Samuels-Lev, D.J. O'Connor, D. Bergamaschi, G. Trigiante, J.K. Hsieh, S. Zhong, I. Campargue, L. Naumovski, T. Crook, and X. Lu ASPP proteins specifically stimulate the apoptotic function of p53 Mol. Cell 8 2001 781 794
119. C. Spinnler, E. Hedstrom, H. Li, J. de Lange, F. Nikulenkov, A.F. Teunisse, and M. Verlaan-de Vries, V. Grinkevich, A.G. Jochemsen, G. Selivanova, Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX Cell Death Differ. 18 2011 1736 1745
120. J. Yang, A. Ahmed, and M. Ashcroft Activation of a unique p53-dependent DNA damage response Cell Cycle 8 2009 1630 1632
121. C. Rinaldo, A. Prodosmo, F. Siepi, A. Moncada, A. Sacchi, G. Selivanova, and S. Soddu HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA Cancer Res. 69 2009 6241 6248
122. J.T. Patton, L.D. Mayo, A.D. Singhi, A.V. Gudkov, G.R. Stark, and M.W. Jackson Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3 Cancer Res. 66 2006 3169 3176
123. S. Lam, K. Lodder, A.F. Teunisse, M.J. Rabelink, M. Schutte, and A.G. Jochemsen Role of Mdm4 in drug sensitivity of breast cancer cells Oncogene 29 2010 2415 2426
124. I.M. van Leeuwen, M. Higgins, J. Campbell, C.J. Brown, A.R. McCarthy, L. Pirrie, N.J. Westwood, and S. Lain Mechanism-specific signatures for small-molecule p53 activators Cell Cycle 10 2011 1590 1598
125. J. Nicholson, K. Neelagandan, A.S. Huart, K. Ball, M.P. Molloy, and T. Hupp An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasis J. Proteome Res. 11 2012 5464 5478
126. M. Oren Decision making by p53: life, death and cancer Cell Death Differ. 10 2003 431 442
127. S.W. Lowe, E. Cepero, and G. Evan Intrinsic tumour suppression Nature 432 2004 307 315
128. V.V. Grinkevich, F. Nikulenkov, Y. Shi, M. Enge, W. Bao, A. Maljukova, A. Gluch, A. Kel, O. Sangfelt, and G. Selivanova Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis Cancer Cell 15 2009 441 453
129. T. Riley, E. Sontag, P. Chen, and A. Levine Transcriptional control of human p53-regulated genes Nat. Rev. Mol. Cell Biol. 9 2008 402 412
130. M. Huarte, M. Guttman, D. Feldser, M. Garber, M.J. Koziol, D. Kenzelmann-Broz, A.M. Khalil, O. Zuk, I. Amit, M. Rabani, L.D. Attardi, A. Regev, E.S. Lander, T. Jacks, and J.L. Rinn A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response Cell 142 2010 409 419
131. K. Lohr, C. Moritz, A. Contente, and M. Dobbelstein P21/CDKN1A mediates negative regulation of transcription by p53 J. Biol. Chem. 278 2003 32507 32516
132. Y. Shi, F. Nikulenkov, J. Zawacka-Pankau, H. Li, R. Gabdoulline, J. Xu, S. Eriksson, E. Hedstrom, N. Issaeva, A. Kel, E.S. Arner, and G. Selivanova ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis Cell Death Differ. 2014
133. I. Ringshausen, C.C. O'Shea, A.J. Finch, L.B. Swigart, and G.I. Evan Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo Cancer Cell 10 2006 501 514
134. S. Shangary, D. Qin, D. McEachern, M. Liu, R.S. Miller, S. Qiu, Z. Nikolovska-Coleska, K. Ding, G. Wang, J. Chen, D. Bernard, J. Zhang, Y. Lu, Q. Gu, R.B. Shah, K.J. Pienta, X. Ling, S. Kang, M. Guo, Y. Sun, D. Yang, and S. Wang Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition Proc. Natl. Acad. Sci. USA 105 2008 3933 3938
135. G. Selivanova, T. Kawasaki, L. Ryabchenko, and K.G. Wiman Reactivation of mutant p53: a new strategy for cancer therapy Semin. Cancer Biol. 8 1998 369 378
136. M.R. Junttila, A.N. Karnezis, D. Garcia, F. Madriles, R.M. Kortlever, F. Rostker, L. Brown Swigart, D.M. Pham, Y. Seo, G.I. Evan, and C.P. Martins Selective activation of p53-mediated tumour suppression in high-grade tumours Nature 468 2010 567 571
137. D.M. Feldser, K.K. Kostova, M.M. Winslow, S.E. Taylor, C. Cashman, C.A. Whittaker, F.J. Sanchez-Rivera, R. Resnick, R. Bronson, M.T. Hemann, and T. Jacks Stage-specific sensitivity to p53 restoration during lung cancer progression Nature 468 2010 572 575
138. D. Schramek, A. Kotsinas, A. Meixner, T. Wada, U. Elling, J.A. Pospisilik, G.G. Neely, R.H. Zwick, V. Sigl, G. Forni, M. Serrano, V.G. Gorgoulis, and J.M. Penninger The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression Nat. Genet. 43 2011 212 219
139. J. Luo, N.L. Solimini, and S.J. Elledge Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 2009 823 837
140. F. Weinberg, R. Hamanaka, W.W. Wheaton, S. Weinberg, J. Joseph, M. Lopez, B. Kalyanaraman, G.M. Mutlu, G.R. Budinger, and N.S. Chandel Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity Proc. Natl. Acad. Sci. USA 107 2010 8788 8793
141. A.J. Levine, and A.M. Puzio-Kuter The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes Science 330 2010 1340 1344
142. K.E. Wellen, and C.B. Thompson Cellular metabolic stress: considering how cells respond to nutrient excess Mol. Cell 40 2010 323 332
143. E. Hedstrom, S. Eriksson, J. Zawacka-Pankau, E.S. Arner, and G. Selivanova P53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA Cell Cycle 8 2009 3576 3583
144. E.A. Komarova, and A.V. Gudkov Suppression of p53: a new approach to overcome side effects of antitumor therapy Biochem. Biokhimiia. 65 2000 41 48
145. P.G. Komarov, E.A. Komarova, R.V. Kondratov, K. Christov-Tselkov, J.S. Coon, M.V. Chernov, and A.V. Gudkov A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy Science 285 1999 1733 1737
146. L. Hernychova, P. Man, C. Verma, J. Nicholson, C.A. Sharma, E. Ruckova, J.Y. Teo, K. Ball, B. Vojtesek, and T.R. Hupp Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry Proteomics 13 2013 2512 2525
147. C.F. Cheok, A. Dey, and D.P. Lane Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination Mol. Cancer Res. 5 2007 1133 1145
148. C.F. Cheok, and D.P. Lane Seeking synergy in p53 transcriptional activation for cancer therapy Discovery Med. 14 2012 263 271
149. K.D. Sullivan, N. Padilla-Just, R.E. Henry, C.C. Porter, J. Kim, J.J. Tentler, S.G. Eckhardt, A.C. Tan, J. DeGregori, and J.M. Espinosa ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53 Nat. Chem. Biol. 8 2012 646 654
150. C.F. Cheok, N. Kua, P. Kaldis, and D.P. Lane Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53 Cell Death Differ. 17 2010 1486 1500
151. B. Rao, I.M. van Leeuwen, M. Higgins, J. Campbel, A.M. Thompson, D.P. Lane, and S. Lain Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy Oncotarget 1 2010 639 650
152. S. Sur, R. Pagliarini, F. Bunz, C. Rago, L.A. Diaz Jr.; K.W. Kinzler, B. Vogelstein, and N. Papadopoulos A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 Proc. Natl. Acad. Sci. USA 106 2009 3964 3969